Cordis Announces Scott Drake as Chief Executive Officer

Cordis announced that its Board of Directors has appointed Scott Drake as Chief Executive Officer (CEO) effective immediately. Mr. Drake most recently held the position of Executive Chairman of the Cordis Board of Directors. He will succeed Shar Matin, who has stepped down as CEO.

Scott Drake has been on the Cordis Board of Directors since we acquired Cordis in 2021,” said Hunter Philbrick, H&F partner and Cordis board member. “He has a long history building world-class medical device organizations, bringing to market groundbreaking patient saving innovations and driving commercial excellence – along with the reputation of attracting, retaining, and developing world-class talent. Scott believes in Cordis’ ability to transform the medical industry, and with him as CEO, Cordis will achieve its vision of pioneering breakthrough cardiovascular technologies.”

Mr. Drake has over 30 years of medical device experience including as the President and CEO of the Spectranetics Corporation, where he increased shareholder value from approximately $170 million to $2.2 billion during his six-year tenure. He has served on numerous boards of directors, including Zayo Group Holdings, which Digital Colony and EQT (EQT) acquired for $14.3 billion, Paragon 28, Inc. (FNA), ViewRay (VRAYQ), Bolder Surgical, the Medical Device Manufacturers Association (MDMA), and he has served as the Chairman of Atricure, Inc. (ATRC).

“I want to thank Shar for all he has done to stand Cordis up as an independent company. I have been on the Cordis Board of Directors for over two years, and I am thrilled to be taking on a more active role as CEO,” states Mr. Drake. “We are entering the next phase of the business, where Cordis is launching new products and driving a revolutionary business model with Cordis-X that will benefit our team, customers, patients, and shareholders

 

SourceCordis

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”